Most Popular
-
1
Hybe-Ador feud should have limited effect on Hybe's overall performance: analysts
-
2
First-ever meeting of president, opposition chief set to finally happen
-
3
Blinken calls on China to press N. Korea to end its 'dangerous' behavior
-
4
Experts raise concerns about Japan putting pressure on Naver over Line
-
5
South Korea to launch space security center under spy agency
-
6
More med professors to take day off each week while govt. urges them to stay
-
7
Hybe refutes Ador CEO Min's denial of breach of trust
-
8
S. Korea, Japan could consider simplified entry agreement: Seoul official
-
9
Legoland Korea Resort to open until 9 p.m.
-
10
[Weekender] How DDP emerged as an icon of Seoul
![[Weekender] How DDP emerged as an icon of Seoul](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050915_0.jpg&u=)
![[Weekender] How DDP emerged as an icon of Seoul](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050915_0.jpg&u=)
Ahngook Pharm to adopt Y Biologics’ cancer immune treatment
By 황유미Published : Sept. 27, 2016 - 12:54
[THE INVESTOR] Ahngook Pharm has signed an agreement to adopt Y Biogologics’ immune checkpoint inhibitor, it announced on Sept. 27.
The pharmaceutical company will run non-clinical and clinical trials on the antibody that restores or enhances the immune system’s ability to fight cancer. The treatment has been reported to have less side effects than first generation chemical therapy that attacks normal tissues and to be more effective than the second generation targeted therapy that kills or deters growth of targeted cancer cells.
With the introduction of this new treatment, Ahngook Pharm seeks to strengthen its position in the biopharmaceutical market, which it entered in 2015 with two kinds of long-acting protein drugs.
By Hwang You-mee (glamazon@heraldcorp.com)
The pharmaceutical company will run non-clinical and clinical trials on the antibody that restores or enhances the immune system’s ability to fight cancer. The treatment has been reported to have less side effects than first generation chemical therapy that attacks normal tissues and to be more effective than the second generation targeted therapy that kills or deters growth of targeted cancer cells.
With the introduction of this new treatment, Ahngook Pharm seeks to strengthen its position in the biopharmaceutical market, which it entered in 2015 with two kinds of long-acting protein drugs.
By Hwang You-mee (glamazon@heraldcorp.com)
